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SUMMARY  
Bone metastases are a very common problem in clinical oncology, affecting approximately 
70% of patients with prostate or breast cancer. Radiopharmaceutical therapy has proved 
effective with minimal side effects for treatment of refractory painful skeletal metastases of 
the blastic or mixed type, but administered activities are generally based on  limited series of 
clinical studies without a proven correlation between the activity and the delivered dose to 
metastatic lesions. In bone pain palliation therapy the red marrow is generally the dose-
limiting organ and due to the complex microstructure of the skeleton it has been difficult to 
calculate accurately the dose deposited to this region. Thus, the estimation of dose to the 
skeletal system at the microscopic level has been limited by the lack of a realistic 
characterization of the trabecular bone architecture. The dose distribution to bone marrow of 
metastatic lesions for the bone seeking radiopharmaceutical 
153
Sm EDTMP has been 
evaluated using a Monte Carlo simulation. In this setting a new dosimetric model has been 
developed based on the micro-CT analysis of bone metastases to investigate the morphology, 
topology and texture of bone samples based on assessment of the micro-structural parameters 
classically evaluated with histomorphometry. The distribution of radiation dose and the mean 
absorbed dose per unit cumulated activity (S value) were computed for bone marrow space.  
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INTRODUCTION 
Bone metastases are a very common problem in clinical oncology, affecting a large number 
of patients with different primary tumors. Approximately 70% of patients with prostate or 
breast cancer and 35% of those with advanced lung, thyroid, and kidney cancers will develop 
painful skeletal metastases which cause considerable morbidity and, ultimately mortality (1). 
Bone metastases are generally classified as either osteolytic or osteoblastic, reflecting 
dysregulated bone destruction or bone formation as the predominant mechanism. Certain 
characteristics of cancer-related pain, including its multifocal nature, severity, heterogeneity, 
progressive nature, and other special challenges, distinguish it from most other types of 
chronic pain. The management of bone pain is a challenging clinical problem and involves a 
multidisciplinary approach which includes analgesics, hormone therapies, bisphosphonates 
and external beam radiation (2). Systemic radiopharmaceutical therapy, either as 
monotherapy or combined with radiosensitisers or chemotherapeutics, has proved effective 
with minimal side effects for treatment of refractory painful skeletal metastases of the blastic 
or mixed type (3). The radiopharmaceuticals include 
89
Sr-chloride (
89
SrCl2), 
186
Re-1-1-
hydroethylidene diphosphate (
186
Re-HEDP) and 
153
Sm-ethylene diamine tetramethylene 
phosphonate (
153
Sm-EDTMP). These agents differ  in terms of efficacy, duration of pain 
palliation, tumoricidal effects, suitability for repeat treatments; toxicity, and cost. Samarium-
153-EDTMP is a complex of radioactive Samarium-153 and a tetraphosphonate 
[ethylenediamine-tetramethylene phosphonic acid (EDTMP)] with high affinity for the 
skeletal tissue, where it concentrates by chemio-absorption in areas of enhanced bone 
turnover. The overall response rate ranges between 65%-80% with complete response in 
10%-30% of the cases associated with mild and reversible hematologic toxicity (4). The 
schedules and radioactivity administered activities, derive from a limited series of clinical 
studies, and therefore may be considered empirical (5,6,7,8). The limitation of this 
therapeutic approach is the absence of a clear, well proven relationship between the 
administered activity and the dose delivered to metastatic lesions. Furthermore an accurate 
skeletal dosimetry is important because of the high radiosensitivity of the hematopoietic cells 
contained within the marrow cavities of trabecular bone, as well of the osteogenic cells on the 
surfaces of the bone trabeculae. The difficulty to calculate accurately the dose deposited to 
this region is primarily due to the complex microstructure of the skeleton. The choice of 
optimal administered activities based on dosimetry could lead to a modification in treatment 
plans, also considering the emerging prospective of combined strategies with anti-tumor 
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agents, such as chemotherapy. The radiation dose to bone from bone-seeking 
radiopharmaceuticals has been modeled over the last 40 years. Different models of electron 
transport in trabecular and cortical bone for the adult have been proposed such as the three-
dimensional transport model by Bouchet et all (9,10) based on morphometric data originating 
by the research group of Spiers (11);  from these data the mean absorbed dose per unit 
cumulated activity (S value) has been systematically computed for several bone seeking 
nuclides and geometries (12). The most commonly employed dosimetry model provides only 
a first order of approximation based on the assumptions of homogenous lesion morphology, 
uniform distribution of radioactivity within the lesion and complete energy deposition within 
the lesion by charged particles. The estimation of microscopic dose to skeletal system has os 
fast been limited by the lack of a realistic characterization of the trabecular bone architecture, 
derivable from a direct imaging technique with sufficient spatial resolution to be useful in 
dosimetric models (13). Micro-computed tomography (μCT; micro-CT) is an important 
approach to analyze quantitatively the trabecular bone structure in three dimensions, 
providing direct measurement of trabecular thickness, number thickness and separation 
thickness with high correlation between morphometric analysis performed with μCT and 
conventional histology (14).  Indeed,  dysregulation of the normal bone remodeling process 
of bone resorption and bone formation that ordinarily maintains skeletal integrity leads to 
important alterations in bone structure, assessable with bone histomorphometry. Dosimetry is 
not a trivial issue: the general case requires extensive modelling while patient-specific 
dosimetry requires actual data on activity uptake and the size of the lesions. Integral dose is, 
of course, more difficult to estimate than dose rate as more experimental data are required. 
The Monte Carlo method has provided useful information through the simulation of radiation 
transport and with improved computer technology, more complex methods may be used in 
radiation therapy such as EGS4 and MCNP-4B (15,16). The MCNP (Monte Carlo N-Particle) 
code was developed at Los Alamos Laboratory (Los Alamos, NM) originally as a neutron 
and photon transport for reactor analysis. This method is widely used to solve complex 
physical problems, particularly those involving multiple independent variables through the 
generation of random histories of particles.  
The aim of this study is estimate the delivered radiation doses to bone marrow of metastatic 
lesions for the bone-seeking radiopharmaceutical 
153
Sm EDTMP, using a Monte Carlo 
simulation. The development of a realist model is based on μCT studies of metastatic bone 
sample to obtained a geometric model of secondary skeletal lesion. 
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The clinical problem of bone metastases 
Bone metastasis is a major complication of several solid cancers; approximately 70% of 
patients with prostate or breast cancer and 35%-42% of those with advanced lung, thyroid, 
and kidney cancers will develop pain skeletal metastases which cause considerable morbidity 
and mortality. The dimension of the clinical problem is substantial, since cancers of the 
prostate, breast, and lung account for about 45% of cancers in all sites. Comprehensive 
evaluations must be made to determine the etiology of the pain and any possible complicating 
factors, such as cord compression, neuropathic conditions, and impending pathologic 
fractures. Indeed the annual incidence of skeletal complications is 1.5– 4.0 events per year in 
patients with bone metastasis (1). Despite its clinical relevance, metastasis remains the most 
poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone 
metastasis have been referred to a complex network between cancer cells and the bone 
microenvironment, although the precise molecular mechanisms underlying this process 
remain to be elucidated (17). The molecular mechanism of bone metastases is an area of 
active investigation, resulting in the development of several bone-targeted therapies including 
a monoclonal antibody targeting the receptor activator of nuclear factor (NF)-κB ligand 
(RANKL). Considering the multistep process of tumor metastasis, several of these steps can 
represent a potential target for therapeutic intervention.  
 
The pathophysiology of bone metastases 
The development of bone metastases is a complex process that occurs as a result of a 
pathophysiologic interactium between tumor cells and bone microenvironment involving to 
tumor-cell invasion, cell migration and adhesion, and stimulation of osteoclastic and 
osteoblastic activity. Each of these discrete steps represents cellular interactions caused by 
specific determinants of both the tumor and the tissue. Bone metastases most commonly 
affect the axial skeleton and the proximal ends of the long bones, the ribs, and the spine, that 
are particularly rich in  red bone marrow, this pattern of distribution suggests that properties 
of the circulation within the bone marrow play an important role. In 1942 Batson et al. (18) 
suggested that venous blood in the pelvis and breast flowed not only into the vena cava, but 
also into a vertebral-venous plexus of vessels extending from the pelvis throughout the 
epidural and perivertebral veins and into the thoraco-abdominal wall, head, and neck; this 
system  could facilitate in the local nesting of tumor cells and also  their progression into 
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bone metastases. Liotta and Kohn (19) reported that the distribution of metastases can be 
predicted by the anatomic distribution of blood flow from the primary site in only 30% of 
cases, while specific properties of the tumor cell and features at the metastatic site determine 
where the metastasis occurs in the majority of cases. In physiological conditions bone 
undergoes dynamic remodeling by a coupled and sequential process of osteoclast-mediated 
bone resorption followed by osteoblast-mediated bone formation, that maintains the balance 
between bone formation and degradation.  Systemic factors, local osteoclast-activating 
cytokines and local bone-derived growth factors, such as the parathyroid hormone, thyroxine, 
prostaglandins, bone morphogenic proteins (BMPs), several local and systemic factors that 
are important for bone regulation, including receptors for transforming growth factor β 
(TGFβ), insulin-like growth factor (IGF), and interleukin (IL)-1 and IL-6 contribute to the 
bone remodeling process (20). Osteoblasts express receptors for PTH, prostaglandins, 
estrogen, vitamin D3, and cytokines such as platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), and TGF. Moreover they are involved in the regulation of osteoclast 
differentiation via expression of the receptor activator of nuclear factor (NF)-κB ligand 
(RANKL) on its cell surface (21). The Wnt pathway (Wnt/β-catenin signaling) has recently 
been identified as a major regulator of osteoblast function and bone formation inducing an 
increased bone mass. Several Wnt proteins are expressed by osteoblasts and stimulate 
osteoblastogenesis via distinct mechanisms, including attenuation of peroxisome proliferator-
activated receptor γ (PPARγ)-induced adipocyte differentiation (22). Osteoclasts are derived 
from precursor cells of the monocyte-macrophage lineage that differentiate into inactive 
osteoclasts. RANKL is a potent inducer of osteoclast production  generally expressed on the 
surface of osteoblasts and stromal cells or released as a soluble variant by activated T cells. 
Its production is influenced by osteotropic factors such as parathyroid hormone, 1,25-
dihydroxyvitamin D and prostaglandins (23). Osteoclast production is stimulated by IL-6, IL-
1, prostaglandins, and colony-stimulating factors (CSFs) by osteoblasts, while immune cells, 
such as T cells, produce IL-4, IL-18, and interferon γ, which negatively regulate osteoclasts 
formation. Moreover, osteoclast-mediated secretion of proteases leads to degradation of the 
bone matrix, while the adherence of osteoclasts to the bone surface is found to be critical for 
bone resorption. Metastasis of tumor cells to specific sites in the skeleton is a complex 
multistep process not completely elucidated which includes tumor cell invasion, migration, 
cell matrix adhesion or cell-to-cell adhesions, interaction with endothelial cells, regulation of 
growth factor, and stimulation of osteoclasts and osteoblasts. Cadtherins, integrins, 
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imuunoglobulins, selectins, and CD44 are some of the molecules implicated in loss of 
cellular adhesion that causes cell matrix detachment, invasion, and migration. The bone 
microenvironment is a source of immobilized growth factors like TGFβ, IGF-1, FGF, PDGF, 
BMPs, cytokines, chemokines, calcium ions, and cell adhesion molecules that promote 
growth and proliferation of metastatic cancer cells. Cancer cells also produce cytokines and 
growth factors that directly or indirectly impact osteoclastic bone resorption (24,25). Bone 
lesions are commonly radiographically classified as osteolytic (when bone destruction arises 
by the action of osteoclasts) or osteoblastic (in which sclerotic processes predominate). 
However, a mixed pattern is common in many lesions, and marker studies suggest that both 
resorption and formation occur simultaneously. Osteolytic metastases occur more commonly 
than osteoblastic lesions and have been described in cancers of breast, lung, thyroid, and 
renal origins. Frequent complications of osteolytic metastases are severe pain, pathological 
fractures, life-threatening hypercalcemia, spinal cord compression, and other nerve 
compression syndromes. Calcium released from the bone matrix in the course of this process 
can lead to the hypercalcemia of malignancy (HCM), a serious metabolic condition. 
Osteoblastic metastases, predominant in prostate cancer, are characterized by osteoblast 
proliferation, differentiation, and bone formation. Patients with osteoblastic metastases have 
bone pain and pathological fractures resulting from the poor quality of bone produced by the 
hyperactivated osteoblast (25).  A major complication associated with bone involvement is 
severe pain, with variable intensity and intermittent, which later becomes chronic pain. Bone 
pain is thought to be distinct from neuropathic or inflammatory pain, where there is 
upregulation of the glial fibrillary acidic protein in the spinal cord indicating astrogliosis. The 
exact mechanism of cancer pain is unknown and it is postulated that the pain may be due to 
the presence of tumor in the bone and linked to the extent of osteoclastic activity. Bone 
resorption and tumor growth are the most important factors of pain onset (26). The trabecular 
pattern of bone, indicating  connectivity within the trabecular architecture, is increased in 
bone metastases. The tumor releases osteoclast maturation factors or stimulates osteoblast 
secretion of RANKL and down-regulation of osteoprotegerin, thus resulting in dominant 
resorptive activity (27-28). The acidic microenvironment produced by osteoclasts contributes 
significantly to bone cancer-associated pain through activation of acid-sensitive nociceptors 
that innervate the marrow, mineralized bone, and periosteum. Sensory neurons express 
different acid-sensing ion channels: transient receptor potential vanilloid 1 (TRPV1) and 
acid-sensing ion channel-3 (ASIC-3), sensitized by a decrease in pH in the range of 4.0–5.0. 
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Therapeutic validity would therefore be supported by an appropriate correlation between 
tumor development and activity profiles versus pain intensity. Furthermore, tumors secrete a 
variety of factors that sensitize or directly excite primary afferent neurons, causing the 
sensation of pain. In this setting nerve growth factor (NGF) may directly activate sensory 
neurons that express the TrkA receptor and/or modulate the expression of proteins. The 
quality of bone cancer pain is characterized  by substantial heterogeneity, either due to the 
cancer or resulting from the alteration of distinct bone structures.  Bone cancer seems to 
generate a profound reorganization in the dorsal root ganglia  (DRG) and spinal cord at both 
neuronal and glial levels (29). Breakthrough pain episodes frequently occur as the tumor 
infiltrates the bone matrix. Moreover neoplastic cells seem to secrete a variety of factors that 
sensitize or directly excite primary afferent neurons causing bone pain.  Neuronal 
hyperactivity accompanying hyperalgesia and allodynia is also detected in the spinal cord, 
reflecting the central sensitization phenomena frequently observed in chronic pain states. In 
neuropathic pain, non-nociceptive Aβ fibers are stimulated, increasing neuronal firing 
towards lamina V-VI of the spinal cord. Therefore, Aβ fiber over-activation may be related to 
acidic tumor environment or nerve compression, thus contributing to c-Fos activation (a 
marker of neuronal activity) and the peptide dynorphin (30). In addition to prostaglandins and 
other factors released by the tumor, bone resorption results in the release of protons that will 
stimulate nociceptors. The number of osteoclasts is therefore an indicator of potential bone 
pain onset and should be screened in every bone cancer model. 
 
Radiometabolic therapy with 
153
Sm-lexidronam 
Systemic therapy with radionuclides linked to a bone-seeking agent may be the option of 
choice for the treatment of patients with multiple skeletal localizations, providing a promising 
pain-control strategy (31). The efficacy of bone-seeking radiopharmaceuticals  relies on their 
selective uptake and prolonged retention at sites of increased osteoblastic activity. The exact 
mechanism of action is not fully understood, but it involves the reduction of cytokines and 
growth factors released by tumor anti-inflammatory cells at the interface between tumor and 
normal bone and radiation-induced mechanical factors, such as reduction of periosteal 
swelling (32). 
Several radiopharmaceuticals for treating painful bone metastases have been developed 
(Table 1) and those commercially available include 
89
Sr, 
186
Re chelated with 
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hydroxyethylidene diphosphonate (HEDP) and 
153
Sm chelated with ethylene diamine 
tetramethylene phosphonate (EDTMP).  
  
   
The choice of the radiopharmaceutical is based on the physical characteristics of the 
radionuclide in relation to the extent of metastatic disease, on  the bone marrow reserve and 
on the local availability of the radiopharmaceutical in a given countries. The nature of the 
emissions (β, internal conversion, or Auger electrons) determines the therapeutic suitability 
of the radionuclide, while the particle range influences treatment-related toxicity (33). Beta 
emitters with short half-lives, such as 
186
Re and 
153
Sm, deliver their radiation at higher dose 
rates which may be more therapeutically effective than equivalent doses given at lower dose 
rates. The sources of radiation within bone differ with the radiopharmaceutical used: the 
metallic chelated radiotracers tend to chemically absorb to the trabecular surface, whereas 
32
P 
and 
89
Sr (as the chloride) distribute more widely throughout the bone. Due to the 
heterogeneity of radiopharmaceutical uptake, spicule thickening, and tumor and marrow 
distribution, there is wide  variation in dosimetry estimates described in the literature (34). 
General requirements for an optimal bone-seeking radiopharmaceutical to be employed for 
the palliation of painful bone metastases include a selective uptake and prolonged retention at 
metastatic sites in contrast to normal bone (i.e., a high tumor-to-non tumor ratio), a rapid 
clearance from soft tissues, a good radiochemical stability and acceptable toxicity. 
Furthermore, an appropriate patient selection is crucial for the success of the therapy. Other 
sources of pain, such as vertebral collapse, nerve root entrapment, fracture and visceral pain, 
will not respond to radionuclide therapy. Response is less predictable in patients with a 
Table 1. Main characteristics of 
bone-seeking radiopharmaceuticals 
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predominantly osteolytic pattern of skeletal metastasis, presumably because poor uptake and 
retention result in a lower absorbed radiation dose at the metastatic site.  
153
Sm is reactor-produced in high radionuclidic purity by neutron bombardment of 
152
Sm2O3. 
During  neutron irradiation several low-yield reaction also occur, including spontaneous 
decay of 
153
Sm to stable 
153
Eu, then neutron capture to form 
154Eu, a γ-emitting radioisotope. 
154
Eu-EDTMP can be detected (35); 
153
Sm has a complex decay scheme with X-rays, gamma 
rays and atomic electrons (Auger and conversion) in addition to the dominant beta decay (see 
Table 2) with a physical half-life of 46.3 h. The maximum energy of the beta emissions is 
0.81 MeV and the  mean energy is 0.23 MeV, resulting in an average penetration range of 
0.83 mm in water and a maximum penetration range of 1.7 mm in bone and of 3.1 mm in soft 
tissue. The β-particles provide more than 99% of the dose locally, due to the range of 
electrons of 2-3 mm with energy between 600 and 800 keV, while energy equal to the 
average of the transition of samarium is less than a millimeter (36). This condition permits an 
optimal control of the distribution of the dose, which is almost completely delivered in the 
area of radiotracer uptake. The main gamma emission (103 keV, 29%) allows the evaluation 
of the radiopharmaceutical biodistribution and dosimetric studies, through gamma-camera 
acquisition. 
153
Sm is complexed with EDTMP with a percentage of complexed radionuclide 
exceeding 99%, resulting in a preparation chemically stable and without any appreciable 
decomposition for more than 48 hours (37). 
153
Sm-lexidronam (
153
Sm-EDTMP) is 
commercially available (Quadramet®, Schering, Berlin) as single-dose vials with a 
concentration of 1.3 GBq/ml and a specific activity of 28–65 MBq/µg. The 
radiopharmaceutical shows a rapid and high uptake into the bone, with a lesion-to-normal 
bone uptake ratio equal to approximately  5. It concentrates by chemoabsorption in areas of 
enhanced metabolic activity, associating with the hydroxyapatite crystal of the bone matrix. 
Washout of the radiopharmaceutical from hydroxyapatite is about 20-30 days and its 
redistribution to normal skeleton or marrow in normal bone is negligible (38) Generally, 50% 
or more of the injected dose binds to bone, varying however with on the extent of metastatic 
disease. 
153
Sm-EDTMP biodistribution is nearly identical, to the blood clearance properties of 
99m
Tc-hydroxymethylene diphosphonate (HDP) and 
99m
Tc methylene diphosphonate (MDP). 
The lesion-to-normal bone ratios for 
153
Sm-EDTMP and 
99m
Tc-HDP is about 4 and lesion-to-
soft tissue ratios about 6. Similar data have been reported for 
99m
Tc-MDP (39). 
153
Sm-
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EDTMP is cleared rapidly from the blood following a bi-phasic or tri-phasic exponential 
pattern, (50% with T1/2=2 2 min, 30% with T1/2=225 min and 20% with T1/2=2 300 min).  
One hour after  administration, less than 1% of the dose remains in the circulation, without 
formation of appreciable metabolites (39). Urinary excretion is the main route of elimination 
and is complete within 6 hours. The bladder dose is inversely related to the extension of 
metastatic disease and it shows extremily variability ranging from 12 cGy/GBq to (40) to 
0.964 cGy/MBq (41). A moderate hyperhydration of the patient to increase the frequency of 
bladder voiding is recommended. The red marrow is generally the dose-limiting organ and 
the major toxic effect observed was myelosuppression,  thrombocytopenia being dose 
limiting in 20–42% of patients (42). Major myelotoxic effects occur when the activity 
administered is one order of magnitude higher than the approved activity, as typically occurs 
in the treatment of osteosarcoma; in such conditions stem cell transplantation is required (35). 
Mild to moderate myelosuppression associated with 
153
Sm-EDTM therapy is present in 
approximately 40%-50% of the patients and WHO grade III and IV toxicity is less than 10%. 
Blood count nadirs typically occur 3-5 weeks after treatment and the decline is reversible in 
up to 97% of the patients with  complete recovery within 8 weeks (43). Several retrospective 
studies have shown that bone marrow suppression is primarily related to bone marrow 
involvement, old age, marrow atrophy caused by prior treatments and 
153
Sm-EDTM repeated 
therapy (44). The red marrow absorbed dose may be increased in patients with concurrent of 
radiotherapy or multiple radionuclide treatments.  Administration of approved activity (37 
MBq/kg) has been selected on the basis of  data obtained in relatively small series studies 
aiming at pain control with an acceptable red marrow toxicity, resulting in a marrow dose that 
is generally lower than 2 Gy (43). The marrow absorbed dose ranges from 0.3–
2.1 mGy/MBq, while median value of bone surface absorbed dose is 4.4 mGy/MBq (range 
2.3-6.8 mGy/MBq) (45). Furthermore the relevant variability in the biodistribution suggests 
that the fixed administered activity based on patient weight is not sufficient to optimize the 
treatment (45). A clear relationship between therapeutic efficacy and increase in administered 
activity (not absorbed dose) has not yet been established.  
Localization of the radiopharmaceutical in the bone marrow is minimal due to the rapid 
plasma clearance that makes the red marrow dose from activity in the blood negligible. The 
radiation-induced marrow toxicity is primarily produced by the beta particle irradiation from 
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the 
153
Sm-EDTMP localized on the endosteal surface. The diffusion of radioactivity into the 
bone mineral (if any occurs) can be neglected due to the short half-life of 
153
Sm and thus a 
surface model of deposition is most appropriate. Furthermore, the bone marrow irradiation is 
difficult to establish in the individual patients because of the heterogeneity of the activity 
within a given bone between trabecular and cortical bone and heterogeneity of red marrow 
distribution.  
Thus,  the actual biological response will also be critically dependent on the marrow reserve 
of the individual patient.  A surface model of distribution of 
153
Sm-EDTMP is most 
appropriate to describe the localization onto the bone. Published dosimetric estimations have 
used the MIRD formalism with different S-factors and biokinetic data . The dose estimations 
to bone marrow in published studies are 64.1±18.7 cGy/GBq (40), 1,514±261 Gy/MBq (41), 
1.86 mGy/MBq (36), and 1.03 mGy/MBq (46). 
A transient increase in bone pain (flare phenomena) occurs after therapy in about 10–20% of 
the cases, usually within 72 hours, typically transient, mild and self-limiting and generally 
associated with clinical response (43). Palliation of bone pain has been shown in 70–95% of 
patients. Several studies have reported on the toxic effects and efficacy of increasing doses of 
153
Sm-EDTMP from 27·8 to 1110 MBq/kg. Repeat dosing of 
153
Sm-EDTMP can improve the 
duration of pain response and survival without increasing hematological toxicity (47,48). The 
combination of radionuclide therapy with anti-tumor agents such as chemotherapy with the 
aim of prolonged survival has been evaluated in several studies. The concurrent 
administration of docetaxel and repeated administration of 
153
Sm-lexidronam in patients with 
castration-resistant prostate cancer has shown encouraging results in term of feasibility and 
safety (49,50,51). 
 
Dosimetric models of trabecular bone         
In radionuclide therapy for bone pain palliation the bone marrow, which is contained within 
the marrow cavities of trabecular bone, represents the dose-limiting organ. The trabecular 
bone, characterized by a complex microstructure of network of trabeculae and tissue cavities, 
is also constituted by the endosteum, a layer of connective tissue, populated with osteoblasts 
and osteoclasts another important dosimetric tissue. This complex structure of the trabecular 
bone without a realistic characterization of the bone architecture has limited the accurate 
estimation of the dose deposited by bone-seeking radiopharmaceuticals. However, recently 
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new imaging techniques have permitted the direct and nondestructive imaging of trabecular 
bone with sufficient spatial resolution to allow the construction of internal dosimetric bone 
model (52). The bone models for internal dosimetry have been under investigation over the 
last 40 years, however based on optical scanning data on skeletal samples from a few 
individuals.   
 Previous dosimetric models of the skeleton are based on the chord-length distributions 
that represent the distribution of distances between entry and exit points of a trabecular bone 
region, measured by Spiers and colleagues (53,54) The distribution of linear path lengths 
through marrow cavities and trabeculae skeleton of seven bone sites was used as a 
quantitative description of 3D structure of the bone. At the present time these data represent 
the most complete information available on the microstructure of both trabecular and cortical 
bone used in dosimetry. Subsequently, Whitwell and Spiers calculated dose conversion 
factors for seven bone surface-seeking radionuclides (
14
C, 
18
F, 
22
Na, 
32
P, 
45
Ca, 
90
Sr and 
90
Y) 
(55,56) These dose conversion factors were used for deriving radionuclide S values for 
skeletal tissues by Snyder et al. (57,58) The S value and the photon-specific absorbed 
fractions in a heterogeneous phantom, were published in the Oak Ridge National laboratory 
(ORNL) Report No. 5000 (ORNL5000) and subsequently as a part of Medical Internal 
Radiation Dose (MIRD) Pamphlet No.11 (58). The method proposed by the MIRD Commitee 
is a set of general equations which can be adapted to anatomical and kinetic complex models, 
allowing the calculation of the dose absorbed by each organ as a result to incorporation of 
one or more radioisotopes. 
An important limitation of this approach was the use of the conservation of energy and the 
uniform isotropic model, valid in homogeneous media. Three source regions (trabecular 
bone, cortical bone and red marrow) along with two target regions (red marrow and skeletal 
tissue) were considered. In 1979 the International Commission on Radiological Protection 
(IRCP) published the Report No. 30 (59) with the recommended absorbed dose fractions of 
energy. β particles originating on the bone surface, different absorbed doses fraction are 
recommended based on the energy of particles (mean energy < 0.2 MeV and ≥ 0.2 MeV). 
Radiopharmaceutical sources were located on the bone surface when the radionuclide 
physical half-life was less than 15 days or otherwise within the matrix. These absorbed 
fractions were implemented in the MIRDOSE2. The ICRP 30 model is adequate for radiation 
protection, but is not useful in predicting marrow doses in radiometabolic therapy. 
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In 1985 Eckerman et al (60) reported a 1-dimensional model of electron transport, extending 
the methods of Spiers to radionuclides within the marrow to provide for dose conversion 
factors seven skeletal regions in computational models. This model provided direct 
calculations of absorbed dose to the bone marrow and the development of dose-volume 
histograms, which show what fractions of the marrow receive different absorbed doses. The S 
values derived were implemented in MIRDOSE3. In MIRDOSE3 the target regions are 
considered the red marrow, the cortical bone volume, the trabecular and cortical bone surface.  
 This model, similarly as the Spiers’s model, is based on the assumptions that the 
particle trajectories are linear through both the bone matrix of the trabeculae and the marrow 
cavities. Furthermore the energy loss within these structures is considered under the 
continuous slowing-down approximation and the transport of energy by delta rays and 
bremsstrahlung photons are ignored. Bouchet et al (61) developed a three-dimensional 
electron transport using the chord length distribution published by Spiers et al, considering 
the electron backscatter, delta rays and bremsstrahlung photons to derive radionuclide S 
values for 22 skeletal sites (62). Three source and target regions (the trabecular marrow 
space, the trabecular bone endosteum, and the trabecular bone volume) are considered. The 
values calculated were similar to those of the Eckerman model at most energy, when 
corrected to the same input assumptions. This model differs from the other in the definition of 
the red marrow region, of the surface source of activity and in the assumption applied in 
transporting electrons through the trabecular endosteum. The S value of bone marrow 
considered as source and target calculated by Eckerman are 50% lower than those calculated 
by Bouchet et al. The different assumption was the consideration of the marrow cellularity in 
the first case. The dose factors in the Bouchet model for bone surface sources result highest, 
assuming that the source is distributed in the endosteum, considerated instead  part of the red 
marrow by Eckerman. The most commonly employed dosimetry model provides only a first 
order of approximation based on the assumptions of the homogenous lesion morphology, 
uniform distribution of radioactivity within the lesion and complete energy deposition within 
the lesion by charged particles. The MIRD 11 model gives marrow S values for the reference 
adult male, while the Eckerman, Bouchet et al., and “revised” models give doses to different 
regions of the skeleton, and for adult males and females, as well as for children.  Trabecular 
bone dosimetric model designed specifically to calculate the dose from the surface-seeker 
186
Re, measuring chord length distributions of cavities and bone trabeculae on 25 samples 
from skeletal metastases (63). Bone trabeculae were then represented by ellipsoids located in 
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an infinite marrow-tissue medium. The transport of electrons was simulated in a three-
dimensional geometry using the Monte Carlo electron transport code EGS4. The 3D radiation 
transport techniques based upon images acquired with NMR microscopy showed that the 
Eckerman model underestimates values of the absorbed fraction for self-irradiation of the 
active marrow at energies below 200 keV and that Bouchet et al. model overestimates these 
same values at energy exceeding 20 keV. Neither model accurately predicts the absorbed 
fraction in the energy range of 20 keV to 200 keV. Probably for some radionuclides, 
depending on physical half-life and radiochemical features , the “bone surface” sources,  may 
be better represented as being distributed in a thin layer close to bone (as in the Eckerman 
model) or throughout the endosteal space (as in the Bouchet et al. model) (64). At the present 
time the Eckerman model is recommended, as well as reported by the ICRP in several 
publications. In 1995 Samaratunga et al (65) developed a complex trabecular model to 
calculate the dose to bone metastases from 
186
Re-HEDP. The geometric model was obtained 
from histomorphometric measures and the deposition pattern of the radiopharmaceutical was 
evidenced by autoradiographic data.  
MATERIALS AND METHODS 
The spatial distribution and the delivered radiation doses to bone metastasis for the bone 
seeking radiopharmaceutical 
153
Sm-EDTMP were evaluated. Micro-CT of bone metastatic 
biopsies has allowed the evaluation of the complex bone trabecular morphology. The micro-
architectural parameters calculated have been used to develop a geometrical model used for 
Monte Carlo simulation.  
 
Analysis of  trabecular bone structure with micro-computed tomography 
Estimation of a realistic bone microstructure is required to better develop radiation dosimetry 
models. Traditionally, the quantification of structural parameters in vitro, in terms of 
morphology, topology, and texture, was based on histomorphometry of two-dimensional 
(2D), with high spatial resolution and high image contrast. However this destructive method 
does not allow further measurements, such as analysis in different planes. The structural 
parameters are measured from sections, and the third dimension is added on the basis of 
stereology. Nondestructive 3D imaging of trabecular bone, such as micro-computed 
tomography (μCT; micro-CT) and micro magnetic resonance imaging (µMRI), can quantify 
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accurately the structural properties of bone, showing an excellent agreement with the indices 
assessed from conventional histomorphometry (66). The development  of the first micro-CT 
system was pioneered by Feldkamp et al. (67) for the 3D analysis in vitro of small bone 
sample with a resolution of 50 µm. The creation of a digital model of bone trabecular with 
µCT has allowed the comparison of 2D and 3D structural analysis methods and the 
development of algorithms to calculate the classic structural parameters. Several studies have 
shown that 3D imaging method, with a resolution ranging from 15 to 30 µm, quantifies with 
high correlation the structural properties of bone compared to conventional 
histomorphometry (66,68). A resolution of 20 µm is considered adequate without invalidating 
a comparison with stereology performed on 2D sections obtained at a section thickness and 
pixel size of 10 μm.  
Several micro-architectural parameters have been developed to describe the bone 
structure, based on Parfitt’s principles of the “plate and rods” model and derived by the 
measurements of trabecular surfaces and perimeters of the samples. These descriptors are the 
trabecular thickness, trabecular number (a measure of plate density) and trabecular separation 
(a measure between trabeculae) and it can be obtained as direct 3D model-independent 
measurement (69). Other parameters have been developed based on stereology and 3D 
imaging, using techniques independent of surfaces and perimeters measures. In this setting 
the fundamental parameters for describing trabecular bone include the bone volume/tissue 
volume ratio, the anisotropy, the connectivity density and the structure model index.  
The bone volume/tissue volume (BV/TV, %) value estimates the quantity of bone and 
it is calculated by the number of voxels in the volume of interest (VOI) considering the total 
numbers of voxels in the VOI. Anisotropy is an important parameter to describe the 
architecture, defining the orientation of trabeculae. Connectivity density express the number 
of trabecular connection per cubic millimeter (1/mm
3
) and it represents the number of the 
element that may be removed without structural alterations, consisting in the split into two 
parts. It is derived from the Euler number, as (1-Euler Number)/VOI. The Euler number is the 
number of particles of a structure plus the number of enclosed cavities minus the connectivity. The 
structure model index (SMI) estimates the plate-rod characteristics of the structure, ranging 
from 0, if the network is mainly composed of plates, to 3 when rods prevail. 
Twenty one bone samples of metastatic tumors have been analyzed by a micro-CT with 
resolution 20x20x20 μm3 (X-ray voltage 70 kVp). The primary cancer was prostate 
carcinoma in 15 cases, colon cancer in 4 cases and breast and lung carcinoma in the 
18 
 
remaining 2 samples, respectively. The diagnosis was confirmed histologically. The mean 
total tissue volume (TV) of the samples, such as the bone volume (BV) and bone 
volume/tissue volume (BV/TV,%) was directly measured by 3D images. These parameters 
were calculated using distance triangulation model, without the necessity of a prior model. 
This approach was also used for the evaluation of the connectivity density (ConnD), the 
triangulated Structure Model Index (TRI-SMI), the trabecular thickness (Tb.Th), trabecular 
number (Tb.N) and trabecular separation (Tb.Sp). The apparent attenuation (total attenuation 
of x-ray beam through entire biopsy sample) due to bone mineral and bone marrow contents 
and the bone attenuation due to the attenuation of x-ray beam due to the mineral bone 
component, were also evaluated for each sample. The triangulate surface of trabeculae/bone 
volume (TRI-BS/BV), triangulate anisotropy (TRI-DA) and Heigen vectors (TRI-|Hx|) were 
calculated based on plate model. The micro-structural descriptors of the prostate bone 
metastases were compared to other primary tumors using the Mann-Whitney U-test and the 
statistical significance was defined as P <0.05. 
 
Monte Carlo simulation  
The Monte Carlo method is a computational technique based on statistical physics, differing 
from deterministic transport methods which solve the transport equation for the average 
particle behavior. Therefore Monte Carlo is useful to solving complicated three-dimensional 
time-dependent problems. The Monte Carlo N-Particle (MCNP) code was developed during 
the Manhattan Project at Los Alamos Laboratory (Los Alamos, NM) during World War II, 
originally as a neutron and photon transport for reactor analysis. It is capable to simulate 
photon and electron transport down to energy of 1 KeV.  In this work Monte Carlo based 
code MCNP5 (70) was used to evaluated the transport of electrons emitted by 
153
Sm from  
trabecular bone. The mean dose per unit cumulated activity (S value) was calculated 
considering the bone marrow space as target region. The marrow space is considered the 
volume between bone trabeculae excluding the endosteal layers, differing from bone marrow 
cavity in which the total volume into the trabeculae is considered. The dose distribution 
within a bone marrow spaces is evaluated considering a discrete model, or rather subdividing 
the target region in several equal zones and evaluating in each regions the S value. The 
selected data library cross-section was the EDNF/B-VII (71). The energy deposition function 
tally *F8 (70) was used to score the doses in unit MeV per starting particle per tally volume, 
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to obtained S value (Gy/decay). The source distribution was modeled using an isotropic 
distribution with an average value of 0.2246 MeV. Periodic boundary condition were used at 
the interfaces (70). The elemental compositions are derived from ICRU Reports 44 and 46. 
The NPS option was used with 1.0x10
6
 electron histories simulated with a standard deviation 
of 10
-4
. All the estimated standard deviations resulting from MCNP5 calculations reported 
hereafter should be intended at the 68% of the confidence level. Only electron were 
considered in the dose calculation, whereas the contribution of γ-photon to the S value was 
considered negligible and ignored. 
153
Sm was assumed to be distributed homogeneously on 
the bone surface. The simulation time was about 16 hours using current generation Intel CPU 
(INTEL®, “Quad-Core Intel® Xeon® processor 5400 Series, INTEL® Datasheet).  
 
RESULTS AND DISCUSSION 
The micro-structural parameters calculated based on µCT analysis of the metastatic bone 
samples using distance triangulation model are summarized in Table 2. The mean total tissue 
volume (TV) of the samples was 107 ±24 mm
3 
with a percent coefficient of variation (CV%) 
of 9 and the bone volume/tissue volume (BV/TV,%) value estimated was 0.37 ± 0.1, with 
CV% of 27. The apparent attenuation and bone attenuation/cm was respectively 1.73±0.5 and 
3.38±0.74. The triangulate surface of trabeculae/bone volume (TRI-BS/BV), triangulate 
anisotropy (TRI-DA) and Heigen vectors (TRI-|Hx|) were also calculated.  
 
The micro-structural descriptors of the prostate bone metastases were compared to other 
primary tumors.  Two groups differ statistically in terms of Tb.th, apparent and bone 
attenuation, TRI-BS/BV, and TRI-DA (see fig1). The trabecular thickness in prostate bone 
Table .2 Main 
microstructural parameters 
calculated 
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metastases was significantly lower than in the other group (p<0.01), as also were the apparent 
and bone attenuation (p<0.01).  TRI-BS and TRI-BS/BV in prostate bone metastases was 
higher than in the other group (p<0.01), and anisotropy resulted significantly lowest (p<0.01).  
 
 
 
 
A geometrical model of trabecular bone was developed based on these structural of 
metastatic trabecular bone, resulting in a set of several concentric hexagonal prisms 
containing respectively from the center to the periphery the bone marrow, the 
osteoblast/osteoclast layer, and the bone trabecula. The radionuclide sources were 
homogeneously included in a thin layer of osteoid of 5 µm. The bone marrow space has a 
diameter of 650 µm, and the bone trabecular thickness of 150 µm. (see Fig. 2). 
 
Fig. 1 Statistical results 
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The electron path length of 
153
Sm is obtained considering one source point and the symmetry 
of the model. Indeed the collision track length of electrons emitted from a source of 
153
Sm  in 
a bone space is the result of the distribution in the contiguous bone trabeculae. The β-
particles emitted in all bone trabeculae lead to the collision track in a single cavity which is 
shown in Figure 3.  
 
 
Moreover, multiple sources located in different trabeculae have been simulated and the 
respective track electrons are obtained (see Fig. 4). The electron path length represented in 
the trabeculae and marrow cavities is the results of the electron irregular paths through the 
material due to the progressive loss of the energy. This track length is determined by the 
reduction of the kinetic energy due to ionizations and formation of Bremsstrahlung radiation 
resulting in changes of directions.   
Fig. 2 Schematic  representation of 
geometrical model developed. 
Fig .3 Collision track length of electrons (in 
blue) from a source of 153Sm. Periodic 
boundary condition is used at the interfaces 
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In this work the dose distribution within a bone marrow spaces is found to be homogenous, 
without significantly difference increasing the depth from the surface of the radiation source. 
These results have been obtained with the quantification of the mean dose per unit cumulated 
activity in discrete areas of the bone marrow space (see Fig. 5).  
  
 
The radiation dose distribution calculated for uniform activity distribution is reported in 
Figure  6 (mm). Our calculations produced S-values between the maximum of 1.9E-7 Gy/Bq 
s closed to radionuclide source until the minimum of 1.6E-7 Gy/Bqs, increasing the distance 
from the source region. The decrease in S value (0.3E-7, 16%) is present in the first 100 µm, 
becoming substantially constant with the rise of the distance between the source and the 
center of the target region (1.60E-07). The mean S value calculated in bone marrow space is 
found to be 1.67e
-07
 Gy/(Bq*s). The dose distribution within the trabecular bone from high 
Fig. 4 Collision track length of electrons 
(in blue) from multiple sources of 
radionuclide in several contiguous 
trabeculae 
Fig. 5 Discretized bone marrow 
cavity used in Monte Carlo 
simulation 
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energy electrons has been shown to be correlated to the size of bone cavities. Indeed the 
equality of the absorbed fractions is due to the range of beta particles that results sufficient to 
traverse several bone space, establishing an energy deposition pattern which is largely 
independent of the radionuclide source.  
 
 
On the basis of this work the radiation dose delivered from 
153
Sm to bone marrow differs 
considerably compared to this estimated in previous dosimetric model and implemented in 
MIRDOSE, resulting in a significantly lower value. Moreover,  IRCP Publication 30 suggests 
an energy-independent absorbed fraction of 1.0, grossly overestimating the radiation dose at 
moderate to high electron energies. Most estimates of absorbed dose are based on 
calculations made for mathematical phantom of the body with a homogeneous representation 
of the bone, which is adequate for transport consideration, but does not consider that the 
transport of energy by secondary electrons. Indeed, the secondary particles generated in 
mineral regions may contributed significantly to the calculation of absorbed dose, especially 
for photon energy of about 200 keV. In addition, the problem of an overestimation of the 
absorbed dose in the active marrow was due to the assumption that the bone marrow absorbs 
energy as efficiently as the mineral regions. These limitations resulted from the lack of 
planning the complexity of the bone in a realistic way. Certainly the bone microstructure 
plays an important role in determining the absorbed dose in a target region. In this setting the 
influence of the regional microstructure in normal bone on the absorbed fraction dose is 
clearly showed in the three-dimensional transport model of Bouchet et al. The modification 
of this parameter is due to the different size of bone trabeculae and marrow cavities. The 
Fig 6 S value spatial distribution 
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absorbed fraction dose to the parietal bone compared to cervical vertebra or rib is found to be 
markedly different because of the larger bone trabeculae and smaller marrow cavities, with a 
more rapid fall with the increase of electron energy.  Our data show that the bone marrow 
space is significantly smaller than the mean marrow space chord length used in previous 
dosimetric model and based on the chord-length distributions, representing one of the 
possibly explanation of the achievement of different results. The geometrical model presented 
differs substantially from previous dosimetric model in terms of the method used to evaluate 
the bone structure and especially in the consideration of a bone metastases model. It should 
be remember that the marrow cavity and trabecular chord length distributions published by 
Spiers et al. were obtained analyzing only seven bone site in a 44-year old man. Furthermore 
the chord-length distributions were calculated by optically scanning the trabecular bone under 
conditions of gamma randomness with the assumption that the track of a particle was straight. 
The total track could be approximated by alternating the chord lengths in trabeculae and 
cavities selected randomly from the measured distributions. Moreover, the analysis of the 
bone microarchitecture of the bone metastases from prostate cancer has shown significant 
differences in the structural parameters compared to normal tissue and degenerative 
osteosclerosis. The BV/TV, BS, Tb.N, ConnD in bone metastases was found to be 
significantly higher than in the normal tissue, indicating evident structural changes in 
secondary skeletal lesions. The metastatic tissue presents variable alterations leading to a 
difficult generalization of a dosimetric model, not considering the extreme individual 
variability in terms of change in bone marrow cellularity and metastatic involvement.  
 
CONCLUSION  
In radionuclide bone palliation the hematopoietic cells in the bone marrow are the dose-
limiting tissue. The schedules administered activity (37 MBq/kg), derive from data obtained 
in a limited number of studies aiming at pain control with an acceptable toxicity. The choice 
of optimal activities based on dosimetry could lead to a modification in treatment plans, 
resulting in the optimization of individual therapy consistent in maximizing dose tumor while 
minimizing of the marrow toxicity. The bone marrow dose modeling and the methods of 
calculating the energy deposition from beta-emitters on skeleton have been developed over 
the last 40 years. However the calculation to the bone marrow represents a challenge due to 
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the complex structural architecture of the trabecular bone. The chord length distributions 
measured in the work of Spiers had provided the most complete information available on the 
3-dimensional microstructure of both trabecular and cortical bone, used in internal dosimetric 
studies. The one-dimensional computational models of Spiers and Eckerman are based on the 
assumptions that the particle trajectories are linear such that a given chord length explicitly 
represents the particle path without angular scatter and that the energy loss within these 
structures can be treated under the continuous slowing-down approximation. Subsequently 
three-dimensional electron transport models for assessing absorbed fraction to trabecular 
bone marrow have been developed and from these the mean absorbed dose per unit 
cumulated activity (S value) has been systematically computed for several bone-seeking 
nuclides and different geometries. The most commonly employed dosimetric model provides 
only a first order of approximation based on the assumptions of the homogenous lesion 
morphology, uniform distribution of radioactivity within the lesion and complete energy 
deposition within the lesion by charged particles, considering the chord length distributions 
as structural information. Indeed the radiation dose delivered from 
153
Sm to bone marrow 
metastases considering the variable micro-structural alterations of skeletal secondary lesions 
is not a trivial issue. In this work the dose distribution of the beta particles originating from 
153
Sm-EDTMP through bone marrow cavities and trabeculae are evaluated based on a Monte 
Carlo simulation in a new dosimetric model.  A realistic approach regarding the bone micro-
structure was used. The micro-CT analysis has allowed the investigation of morphology, 
topology, and texture of bone metastases with the calculation of structural parameters 
classically evaluated with histomorphometry. This preliminary evaluation has lead to the 
development of a geometrical model of metastatic trabecular bone. The radiation dose 
distribution appears to be homogeneous in the central region of bone marrow space, while at 
the periphery of the cavity in the proximity of radiation source seems to be significantly 
higher. The  S value computed for bone marrow space differs considerably compared to this 
estimated in previous dosimetric model, confirming the limitations of the previous establish 
data in the evaluation of metastatic lesions.  Therefore the update of these models for more 
patients specific application may provide optimization of administered activity with a reliable 
dose calculation.  
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